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Background
To contain costs of medicines, many countries have intro-
duced policies aiming to lower prices of generics [1].
Measures taken in Austria include Generic Price Linkage
and in Finland Generic Substitution and Reference Pricing,
where competition plays a crucial role.
Objectives
The aim of this study is to assess the Generic Price
Linkage system and the system that includes Generic
Substitution and Reference Pricing by comparing prices
of generics and originators and the number of generics
entering the market in Austria and in Finland.
Policies targeted: Generic Price Linkage, Generic Sub-
stitution, Reference Pricing.
Stakeholders: Austria: Main Association of Austrian
Social Security Institutions, pharmaceutical industry,
patients. Finland: Finnish Medicines Agency, Pharma-
ceuticals Pricing Board, Social Insurance Institution,
pharmaceutical industry, pharmacies, patients.
Region covered: EURO, Austria and Finland.
Methods
Study design: Policy evaluation. Time series design was
used to estimate changes in price levels.
Time period: 2009–2013.
Setting: Pharmaceuticals used in outpatient care and
prescribed either in the public or private sector. Ten
active ingredients with high sales in Finland and reim-
bursable in both countries were included in the analysis.
Interventions: Prices of original products whose patent
protection expired during 2010–2012 and generics com-
parable with them were analysed 6 months before and
12 months after generic entry. Price levels were mea-
sured in wholesale prices proportioned to the number of
Defined Daily Doses in the package (EUR/DDD).
Results
One year after generic entry, prices of the originators had
fallen, on average, by 46% in Austria and by 21% in
Finland. Prices of the generics were 66% lower in Austria
and 59% lower in Finland than prices of the originators
before generic entry. The mean number of generics per
active ingredient was 6.3 in Austria and 5.1 in Finland.
Conclusions and lessons learned
Even if uptake of generics is lower in Austria (26% in
volume) than in Finland (36%), the Austrian pricing sys-
tem appears to be more efficient to lower prices. Price
competition in Finland is probably reduced by a concen-
trated generic market.
It has been stated that free competition lowers generic
prices more efficiently than linking the price of a generic
to the price of the originator [2]. That is not necessarily
the case. Success of a policy measure also largely depends
on how the details of the measure are constructed.
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